Aditya Juloori, MD

Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer: The DEPEND Phase 2 Nonrandomized Clinical Trial.
Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer: The DEPEND Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2025 May 01; 11(5):492-501.
PMID: 40048190

Patient-specific modeling of radiation-induced lymphopenia for head and neck cancer.
Patient-specific modeling of radiation-induced lymphopenia for head and neck cancer. Med Phys. 2025 Apr 14.
PMID: 40229136

Rationale for Investigation of Neoadjuvant Chemoimmunotherapy Before Chemoradiation in Unresectable Stage III Non-Small Cell Lung Cancer.
Rationale for Investigation of Neoadjuvant Chemoimmunotherapy Before Chemoradiation in Unresectable Stage III Non-Small Cell Lung Cancer. J Clin Oncol. 2025 Mar 27; JCO2402355.
PMID: 40146965

Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas.
Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas. Oral Oncol. 2025 Apr; 163:107207.
PMID: 40043423

NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025.
NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025. J Natl Compr Canc Netw. 2025 02; 23(2):2-11.
PMID: 39938471

Delays in phases of care from identification to treatment of suspicious lung nodules.
Delays in phases of care from identification to treatment of suspicious lung nodules. JTCVS Open. 2025 Apr; 24:451-471.
PMID: 40309697

American Radium Society Appropriate Use Criteria on Cardiac Toxicity Prevention and Management After Thoracic Radiotherapy.
American Radium Society Appropriate Use Criteria on Cardiac Toxicity Prevention and Management After Thoracic Radiotherapy. J Thorac Oncol. 2024 Dec; 19(12):1654-1667.
PMID: 39313150

Appropriate Use Criteria (AUC) for the Management of Non-Small Cell Lung Cancer in a Central/Ultra-Central Location: Guidelines from the American Radium Society.
Appropriate Use Criteria (AUC) for the Management of Non-Small Cell Lung Cancer in a Central/Ultra-Central Location: Guidelines from the American Radium Society. J Thorac Oncol. 2024 Dec; 19(12):1640-1653.
PMID: 39271016

DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer.
DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer. Clin Lung Cancer. 2024 Dec; 25(8):e448-e452.
PMID: 39242330

Safety of combined ablative radiotherapy and immune checkpoint inhibitors in three phase I trials.
Safety of combined ablative radiotherapy and immune checkpoint inhibitors in three phase I trials. Eur J Cancer. 2024 Sep; 209:114264.
PMID: 39106643